{"id":57906,"date":"2026-02-25T13:36:02","date_gmt":"2026-02-25T05:36:02","guid":{"rendered":"https:\/\/flcube.com\/?p=57906"},"modified":"2026-02-25T13:36:02","modified_gmt":"2026-02-25T05:36:02","slug":"pharscin-pharmas-parp7-inhibitor-hsn002066c1-wins-nmpa-ind-approval-first-class-1-1-innovative-drug-enters-clinic","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57906","title":{"rendered":"Pharscin Pharma&#8217;s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval \u2013 First Class 1.1 Innovative Drug Enters Clinic"},"content":{"rendered":"\n<p><strong>Chongqing Pharscin Pharmaceutical Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/002907:SHE\">SHE:\u202f002907<\/a>)<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved the <strong>Investigational New Drug (IND)<\/strong> application for <strong>HSN002066C1 tablets<\/strong>. The <strong>selective PARP7 inhibitor<\/strong> is authorized for <strong>Phase I clinical trials<\/strong> as a <strong>monotherapy for advanced solid tumors<\/strong>, marking Pharscin&#8217;s <strong>first Class\u202f1.1 innovative drug<\/strong> to enter clinical development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:\u202f002907)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HSN002066C1 tablets<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Class\u202f1.1 innovative drug (first for Pharscin)<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>NMPA IND approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced malignant solid tumors (monotherapy)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Selective small\u2011molecule inhibitor of PARP7 (poly ADP\u2011ribose polymerase 7)<\/td><\/tr><tr><td><strong>IP Status<\/strong><\/td><td>Independently developed with full intellectual property rights<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Oral<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-hsn002066c1\">Drug Profile \u2013 HSN002066C1<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>PARP7<\/strong> \u2013 a mono\u2011ADP\u2011ribosyltransferase involved in DNA damage response, immune regulation, and cellular stress pathways<\/li>\n\n\n\n<li><strong>Class:<\/strong> <strong>Selective small\u2011molecule inhibitor<\/strong> (distinct from PARP1\/2 inhibitors like olaparib)<\/li>\n\n\n\n<li><strong>Selectivity:<\/strong> Potent and highly selective for PARP7 vs. other PARP family members<\/li>\n\n\n\n<li><strong>Innovation Status:<\/strong> <strong>First\u2011in\u2011class<\/strong> PARP7 inhibitor from Pharscin; first Class\u202f1.1 asset in company&#8217;s pipeline<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> IND\u2011approved; Phase I initiation pending<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-evidence\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Finding<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Oral Bioavailability<\/strong><\/td><td>High exposure levels in murine models<\/td><td>Supports once\u2011daily oral dosing in humans<\/td><\/tr><tr><td><strong>Monotherapy Efficacy<\/strong><\/td><td>Significant tumor growth inhibition<\/td><td>Single\u2011agent potential across solid tumor types<\/td><\/tr><tr><td><strong>Combination Potential<\/strong><\/td><td>Enhanced activity in combination settings<\/td><td>Opportunity for synergistic regimens with chemotherapy, immunotherapy, or targeted agents<\/td><\/tr><tr><td><strong>Tumor Model Breadth<\/strong><\/td><td>Activity across various tumor models<\/td><td>Broad applicability in diverse malignancies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Validation:<\/strong> IND approval validates Pharscin&#8217;s <strong>internal R&amp;D capabilities<\/strong> and establishes a pathway for future Class\u202f1.1 innovative assets.<\/li>\n\n\n\n<li><strong>PARP7 Differentiation:<\/strong> Unlike marketed PARP1\/2 inhibitors used in BRCA\u2011mutant cancers, <strong>PARP7 inhibition<\/strong> represents a novel mechanism with potential in <strong>immuno\u2011oncology<\/strong> and <strong>DNA damage response<\/strong> combinations.<\/li>\n\n\n\n<li><strong>Full IP Control:<\/strong> <strong>Complete intellectual property ownership<\/strong> enables Pharscin to pursue global licensing opportunities or retain full commercial rights in key markets.<\/li>\n\n\n\n<li><strong>Solid Tumor Focus:<\/strong> Initial <strong>monotherapy development<\/strong> in advanced solid tumors provides broad patient access for Phase I dose\u2011finding, with potential to narrow to biomarker\u2011selected populations in later stages.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PARP Inhibitor Evolution:<\/strong> The PARP inhibitor market is expanding beyond PARP1\/2 to <strong>PARP7, PARP14, and other family members<\/strong>, with emerging roles in immune modulation and synthetic lethality beyond BRCA mutations.<\/li>\n\n\n\n<li><strong>China Oncology Innovation:<\/strong> NMPA&#8217;s rapid IND approval reflects China&#8217;s supportive regulatory environment for <strong>novel target mechanisms<\/strong> and <strong>domestically developed innovative drugs<\/strong>.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Pharscin joins a growing field of PARP7 developers; early clinical data will be critical for establishing differentiation and partnership attractiveness.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial initiation, safety and efficacy outcomes, and commercial potential for HSN002066C1. Actual results may differ due to risks including Phase I dose\u2011limiting toxicities, competitive program advancements, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u534e\u68ee\u5236\u836f\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u534e\u68ee\u5236\u836f\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-55366a7a-05b9-47ea-8288-6c145f767817\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u534e\u68ee\u5236\u836f\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\">\u534e\u68ee\u5236\u836f\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u534e\u68ee\u5236\u836f\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-55366a7a-05b9-47ea-8288-6c145f767817\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:\u202f002907) announced that China&#8217;s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,3665,3666],"class_list":["post-57906","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-pharscin-pharmaceutical","tag-she-002907"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pharscin Pharma&#039;s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval \u2013 First Class 1.1 Innovative Drug Enters Clinic - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:\u202f002907) announced that China&#039;s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for HSN002066C1 tablets. The selective PARP7 inhibitor is authorized for Phase I clinical trials as a monotherapy for advanced solid tumors, marking Pharscin&#039;s first Class\u202f1.1 innovative drug to enter clinical development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57906\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharscin Pharma&#039;s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval \u2013 First Class 1.1 Innovative Drug Enters Clinic\" \/>\n<meta property=\"og:description\" content=\"Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:\u202f002907) announced that China&#039;s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for HSN002066C1 tablets. The selective PARP7 inhibitor is authorized for Phase I clinical trials as a monotherapy for advanced solid tumors, marking Pharscin&#039;s first Class\u202f1.1 innovative drug to enter clinical development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57906\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-25T05:36:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57906#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57906\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pharscin Pharma&#8217;s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval \u2013 First Class 1.1 Innovative Drug Enters Clinic\",\"datePublished\":\"2026-02-25T05:36:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57906\"},\"wordCount\":488,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Pharscin Pharmaceutical\",\"SHE: 002907\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57906#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57906\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57906\",\"name\":\"Pharscin Pharma's PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval \u2013 First Class 1.1 Innovative Drug Enters Clinic - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-25T05:36:02+00:00\",\"description\":\"Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:\u202f002907) announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for HSN002066C1 tablets. The selective PARP7 inhibitor is authorized for Phase I clinical trials as a monotherapy for advanced solid tumors, marking Pharscin's first Class\u202f1.1 innovative drug to enter clinical development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57906#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57906\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57906#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharscin Pharma&#8217;s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval \u2013 First Class 1.1 Innovative Drug Enters Clinic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharscin Pharma's PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval \u2013 First Class 1.1 Innovative Drug Enters Clinic - Insight, China&#039;s Pharmaceutical Industry","description":"Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:\u202f002907) announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for HSN002066C1 tablets. The selective PARP7 inhibitor is authorized for Phase I clinical trials as a monotherapy for advanced solid tumors, marking Pharscin's first Class\u202f1.1 innovative drug to enter clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57906","og_locale":"en_US","og_type":"article","og_title":"Pharscin Pharma's PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval \u2013 First Class 1.1 Innovative Drug Enters Clinic","og_description":"Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:\u202f002907) announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for HSN002066C1 tablets. The selective PARP7 inhibitor is authorized for Phase I clinical trials as a monotherapy for advanced solid tumors, marking Pharscin's first Class\u202f1.1 innovative drug to enter clinical development.","og_url":"https:\/\/flcube.com\/?p=57906","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-25T05:36:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57906#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57906"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pharscin Pharma&#8217;s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval \u2013 First Class 1.1 Innovative Drug Enters Clinic","datePublished":"2026-02-25T05:36:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57906"},"wordCount":488,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Pharscin Pharmaceutical","SHE: 002907"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57906#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57906","url":"https:\/\/flcube.com\/?p=57906","name":"Pharscin Pharma's PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval \u2013 First Class 1.1 Innovative Drug Enters Clinic - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-25T05:36:02+00:00","description":"Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:\u202f002907) announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for HSN002066C1 tablets. The selective PARP7 inhibitor is authorized for Phase I clinical trials as a monotherapy for advanced solid tumors, marking Pharscin's first Class\u202f1.1 innovative drug to enter clinical development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57906#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57906"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57906#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pharscin Pharma&#8217;s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval \u2013 First Class 1.1 Innovative Drug Enters Clinic"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57906"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57906\/revisions"}],"predecessor-version":[{"id":57909,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57906\/revisions\/57909"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}